Table 1 Baseline characteristics of the patients with cancer who received antineoplastic mAbs (N = 1,067)

Age at mAb initiation in years, Mean ± SD

49 ± 11.77

46.4 ± 10.7

53.2 ± 12.1

42.1 ± 9.9

 < 0.001

Female, n (%)

840 (78.7%)

617 (98.6%)

200 (48%)

23 (100%)

 < 0.001

Body mass index (kg/m²), Mean ± SD

29 ± 6.24

30.6 ± 6.1

26.7 ± 5.7

28.8 ± 5

 < 0.001

Comorbidities, n (%)

Diabetes mellitus

237 (22.2%)

122 (19.4%)

113 (27%)

2 (8.7%)

0.004

Dyslipidemia

68 (6.4%)

42 (6.7%)

26 (6.2%)

0 (0%)

0.427

Anemia

14 (1.3%)

5 (0.8%)

8 (1.9%)

0 (0%)

0.240

Hyperthyroidism

7 (0.7%)

4 (0.63%)

3 (0.7%)

0 (0%)

0.914

Hypothyroidism

66 (6.2%)

43 (6.9%)

20 (4.8%)

3 (13%)

0.151

Hypertension

241 (22.6%)

114 (18.2%)

124 (29.7%)

3 (13%)

 < 0.001

Heart failure

4 (0.4%)

3 (0.48%)

1 (0.24%)

0 (0%)

0.789

Ischemic heart disease

15 (1.4%)

8 (1.3%)

7 (1.7%)

0 (0%)

0.734

Arrhythmia

10 (0.9%)

7 (1.1%)

3 (0.7%)

0 (0%)

0.721

mAb indication and duration of therapy

Breast cancer, n (%)

647 (60.6%)

608 (97.1%)

16 (3.8%)

23 (100%)

 < .001

Gastric cancer, n (%)

16 (2.6%)

16 (2.6%)

0

0

0.003

Endometrial cancer, n (%)

2 (0.3%)

2 (0.3%)

0

0

0.494

Colorectal cancer, n (%)

359 (85.9%)

0

359 (85.9%)

0

 < 0.001

Ovarian cancer, n (%)

11 (2.6%)

0

11 (2.6%)

0

 < .001

Glioblastoma, n (%)

8 (1.9%)

0

8 (1.9%)

0

0.002

Other, n (%)

7 (1.7%)

0

7 (1.7%)

0

0.004

Duration of therapy (months), mean

14.4

16

11.8

12.8

 < 0.001

mAb concomitant medication

Docetaxel, n (%)

474 (44.4%)

455 (72.7%)

6 (1.4)

13 (56.5%)

 < 0.001

Cyclophosphamide, n (%)

68 (6.3%)

67 (10.7%)

1 (0.2%)

0

 < 0.001

Carboplatin, n (%)

45 (4.2%)

38 (6%)

7 (1.7%)

0

0.001

Paclitaxel, n (%)

52 (4.8%)

35 (5.6%)

13 (3.1%)

4 (17.4%)

0.004

Cisplatin, n (%)

20 (1.87%)

18 (2.9%)

2 (0.5%)

0

0.016

Capecitabine, n (%)

90 (8.43%)

12 (2%)

78 (18.6%)

0

 < 0.001

Vinorelbine, n (%)

6 (1%)

6 (1%)

0

0

0.119

Fluorouracil, n (%)

50 (4.6%)

6 (1%)

44 (10.5%)

0

 < 0.001

Doxorubicin, n (%)

9 (0.84%)

3 (0.5%)

5 (1.2%)

1 (4.3%)

0.082

Oxaliplatin, n (%)

247 (23%)

3 (0.5%)

244 (58.4%)

0

 < 0.001

Lapatinib, n (%)

2 (0.3%)

2 (0.3%)

0

0

0.494

Gemcitabine, n (%)

3 (0.28%)

1 (0.2%)

2 (0.5%)

0

0.614

Epirubicin, n (%)

1 (0.2%)

1 (0.2%)

0

0

0.703

Irinotecan, n (%)

134 (32%)

0

134 (32%)

0

 < 0.001

Leucovorin, n (%)

39 (9.3%)

0

39 (9.3%)

0

 < 0.001

Pemetrexed, n (%)

2 (0.5%)

0

2 (0.5%)

0

0.211

Topotecan, n (%)

2 (0.5%)

0

2 (0.5%)

0

0.211

None, n (%)

134 (12.5%)

93 (14.9%)

41 (9.8%)

0

0.010